Diabetes drug semaglutide may fight inflammation and protect arteries

NCT ID NCT07314684

Recruiting now Disease control Sponsor: Federico II University Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 13 times

Summary

This study looks at whether adding semaglutide to standard diabetes care can reduce inflammation and improve blood vessel function in people with type 2 diabetes who are at high risk for heart problems but have not yet had a heart attack or stroke. Researchers will measure blood markers of inflammation and vessel health over 52 weeks in 80 participants. The goal is to understand how semaglutide might help control diabetes-related damage beyond lowering blood sugar.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Azienda Ospedaliera Sant'Anna e San Sebastiano
RECRUITING

Caserta, Caserta, 81100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••
Federico II University
RECRUITING

Naples, Napoli, 80131, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T2DM (TYPE 2 DIABETES MELLITUS) T2DM (TYPE 2 DIABETES MELLITUS)